More on GILD
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $134.32 |
|
|||
| Open | $134.41 | ||||
| 52 Wk High | $108.63 | ||||
| 52 Wk Low | $71.39 | ||||
| Day High | $134.56 | ||||
| Day Low | $132.60 | ||||
| P/E | 73.48 | ||||
| EPS | $1.81 | ||||
| Volume | 1,541,172 | ||||
- Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Q2 Print
- Gilead Sciences (GILD) PT Lowered to $145 at Barclays
- Gilead Sciences (GILD) PT Lowered to $165 at Morgan Stanley
- EU panel backs Gilead's Trodelvy plus Keytruda for breast cancer
- CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
- Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
- Gilead to present lenacapavir HIV trial data at AIDS 2026
- Gilead and Merck HIV pill shows strong results in Phase 3 trials
- Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
- Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
Entities mentioned with GILD
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Options | View Related Stories »
- Show More...
